title: Dystonia.
abstract: OBJECTIVE
  The purpose of this review is to provide an update on the classification, phenomenology, pathophysiology, and treatment of dystonia.
  
  
  RESULTS
  A revised definition based on the main phenomenologic features of dystonia has recently been developed in an expert consensus approach. Classification is based on two main axes: clinical features and etiology. Currently, genes have been reported for 14 types of monogenic isolated and combined dystonia. Isolated dystonia (with dystonic tremor) can be caused by mutations in TOR1A (DYT1), TUBB4 (DYT4), THAP1 (DYT6), PRKRA (DYT16), CIZ1 (DYT23), ANO3 (DYT24), and GNAL (DYT25). Combined dystonias (with parkinsonism or myoclonus) are further subdivided into persistent (GCHI [DYT5], SGCE [DYT11], and ATP1A3 [DYT12], with TAF1 most likely but not yet proven to be linked to DYT3) and paroxysmal (PNKD [DYT8], PRRT2 [DYT10], and SLC2A1 [DYT18]). Recent insights from neurophysiologic studies identified functional abnormalities in two networks in dystonia: the basal ganglia-sensorimotor network and, more recently, the cerebellothalamocortical pathway. Besides the well-known lack of inhibition at different CNS levels, dystonia is specifically characterized by maladaptive plasticity in the sensorimotor cortex and loss of cortical surround inhibition. The exact role (modulatory or compensatory) of the cerebellar-cortical pathways still has to be further elucidated. In addition to botulinum toxin for focal forms, deep brain stimulation of the globus pallidus internus is increasingly recognized as an effective treatment for generalized and segmental dystonia.
  
  
  CONCLUSIONS
  The revised classification and identification of new genes for different forms of dystonia, including adult-onset segmental dystonia, enable an improved diagnostic approach. Recent pathophysiologic insights have fundamentally contributed to a better understanding of the disease mechanisms and impact on treatment, such as functional neurosurgery and nonpharmacologic treatment options.
authors.forename: Francesca
authors.initials: F
authors.lastname: Morgante
authors.forename: Christine
authors.initials: C
authors.lastname: Klein
mesh_terms: D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D001927:Brain Diseases / Q000150:complications; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D015259:Dopamine Agents / Q000627:therapeutic use; D020821:Dystonic Disorders / Q000145:classification* / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics; D055815:Young Adult
chemical_list: D018726:Anti-Dyskinesia Agents; D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D009125:Muscle Relaxants, Central; D001905:Botulinum Toxins